INT313864

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.02
First Reported 2010
Last Reported 2010
Negated 0
Speculated 0
Reported most in Title
Documents 1
Total Number 2
Disease Relevance 2.14
Pain Relevance 0.14

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleus (Tdp2) nuclease activity (Tdp2)
Tdp2 (Mus musculus)
Pain Link Frequency Relevance Heat
Inflammatory mediators 2 75.36 Quite High
Calcium channel 4 69.00 Quite High
headache 6 63.72 Quite High
cva 4 5.00 Very Low Very Low Very Low
carbamazepine 2 5.00 Very Low Very Low Very Low
fibrosis 2 5.00 Very Low Very Low Very Low
adenocard 2 5.00 Very Low Very Low Very Low
Bioavailability 2 5.00 Very Low Very Low Very Low
beta blocker 2 5.00 Very Low Very Low Very Low
Potency 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Pulmonary Hypertension 132 99.22 Very High Very High Very High
Cv General 4 Under Development 44 98.40 Very High Very High Very High
Hyperplasia 2 95.16 Very High Very High Very High
Apoptosis 4 94.08 High High
Reprotox - General 2 10 94.00 High High
Disease 34 83.48 Quite High
INFLAMMATION 2 74.96 Quite High
Pressure Volume 2 Under Development 4 66.44 Quite High
Increased Venous Pressure Under Development 10 64.12 Quite High
Headache 6 63.72 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Sildenafil, an orally administered a phosphodiesterase type 5 (PDE-5) inhibitor, targets the NO pathway.
Negative_regulation (inhibitor) of phosphodiesterase type 5
1) Confidence 0.02 Published 2010 Journal Drug design, development and therapy Section Body Doc Link PMC2880338 Disease Relevance 1.28 Pain Relevance 0.07
Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension

Sildenafil is an orally administered phosphodiesterase type 5 inhibitor that is approved for the treatment of pulmonary arterial hypertension (PAH).

Negative_regulation (inhibitor) of phosphodiesterase type 5 associated with pulmonary hypertension
2) Confidence 0.02 Published 2010 Journal Drug design, development and therapy Section Title Doc Link PMC2880338 Disease Relevance 0.86 Pain Relevance 0.06

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox